insulin glargine
Regulatory milestones approvals, filings & regulatory actions · 7 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | TOUJEO SOLOSTAR | — | 2019-11-26 | fda.gov ↗ |
| Label expansions (4) | US (FDA) | LANTUS SOLOSTAR | — | 2003-05-01 – 2015-07-17 | fda.gov ↗ |
| Approved | EU (EMA) | Lantus | — | 2000-06-09 | europa.eu ↗ |
| Approved | US (FDA) | LANTUS SOLOSTAR | — | 2000-04-20 | fda.gov ↗ |
Trials 285 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02587741 | Jul 2015 → Jul 2023 | diabetic retinopathy | Third Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 133 trials | ||||||
| Phase 1 | NCT07588906 | Feb → Jul 2024 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03945656 | May 2019 → Sep 2021 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT03723772 | Nov 2018 → Jun 2020 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT03555305 | Sep 2018 → Nov 2019 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04236895 | Jul → Nov 2018 | type 1 diabetes mellitus | Gan and Lee Pharmaceuticals, USA | Completed | No outcome recorded |
| Phase 1 | NCT02713477 | Apr → Jun 2016 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT02506647 | Dec 2015 → Sep 2016 | type 1 diabetes mellitus | Gan and Lee Pharmaceuticals, USA | Completed | No outcome recorded |
| Phase 1 | NCT02479022 | Jun → Dec 2015 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02201199 | Aug → Nov 2014 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01981031 | Nov → Dec 2013 | type 1 diabetes mellitus | Adocia | Completed | No outcome recorded |
| Phase 1 | NCT01838083 | Apr → Aug 2013 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01809184 | Mar → Sep 2013 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01730014 | Oct 2012 → Jul 2013 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01704417 | Oct 2012 → Mar 2013 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01688635 | Sep 2012 → Feb 2013 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01676233 | Sep 2012 → Aug 2013 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01634165 | Jul → Sep 2012 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01597713 | May → Oct 2012 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01493115 | Nov 2011 → Apr 2012 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01476345 | Nov 2011 → Jul 2012 | diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01357603 | Jun 2011 → May 2012 | type 1 diabetes mellitus | Wockhardt | Completed | No outcome recorded |
| Phase 1 | NCT01334034 | Apr → Sep 2011 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01349855 | Mar → May 2011 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01195454 | Aug → Nov 2010 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01146678 | Jun → Sep 2010 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01002768 | Oct 2009 → Mar 2010 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT00961324 | Jul → Oct 2009 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01868529 | Jan → Jun 2008 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT00824668 | Aug → Oct 2007 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT00574912 | Mar 2007 → Sep 2009 | type 2 diabetes mellitus | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT01497574 | May → Oct 2005 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT00184613 | May 2005 → Jan 2006 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT00348972 | Feb 2002 → ? | diabetes mellitus, hyperglycemia | Sanofi | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01053728 | Feb → May 2010 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 210 trials | ||||||
| Phase 2 | NCT07461103 | Jun 2024 → Aug 2025 | pemphigus vulgaris | Alexandria University | Completed | No outcome recorded |
| Phase 2 | NCT05155917 | Mar 2022 → Jan 2024 | diabetic ketoacidosis, hyperglycemia | Changhua Christian Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04542148 | Feb 2022 → Nov 2025 overdue | gestational diabetes, type 2 diabetes mellitus | University of Alabama at Birmingham | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04591457 | Oct 2020 → Aug 2021 | diabetes mellitus | Indonesia University | Unknown | No outcome recorded |
| Phase 2 | NCT03352674 | Sep 2016 → Dec 2018 | type 2 diabetes mellitus | Indonesia University | Completed | No outcome recorded |
| Phase 2 | NCT01910194 | Dec 2013 → Oct 2014 | diabetes mellitus | Profil Institute for Metabolic Research GmbH | Completed | No outcome recorded |
| Phase 2 | NCT01399645 | May 2011 → Jun 2014 | NAFLD1, metabolic dysfunction-associated steatohepatitis, type 2 diabetes mellitus | University of Montreal Hospital Centre (CHUM) | Completed | No outcome recorded |
| Phase 2 | NCT01049412 | Jan → Dec 2010 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00764556 | May 2008 → May 2009 | chronic obstructive pulmonary disease, hyperglycemia | St George's, University of London | Completed | No outcome recorded |
| Phase 2 | NCT00612040 | Jan → Jun 2008 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 375 trials | ||||||
| Phase 3 | NCT06881264 | Apr 2024 → Sep 2025 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT06340854 | Apr 2024 → May 2025 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT06269107 | Feb 2024 → May 2025 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT05545800 | Sep 2022 → Jun 2024 | type 2 diabetes mellitus | Xiangya Hospital of Central South University | Unknown | No outcome recorded |
| Phase 3 | NCT05514535 | Aug 2022 → Mar 2025 | obesity disorder, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT04310280 | Jun → Dec 2019 | chronic venous insufficiency, ulcer of lower limbs | Hospital Central "Dr. Ignacio Morones Prieto" | Completed | No outcome recorded |
| Phase 3 | NCT03767543 | Mar 2019 → Oct 2020 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT04022993 | Jul 2018 → Feb 2019 | type 1 diabetes mellitus | Geropharm | Completed | No outcome recorded |
| Phase 3 | NCT03371082 | Oct 2017 → Aug 2019 | type 1 diabetes mellitus | Gan and Lee Pharmaceuticals, USA | Completed | No outcome recorded |
| Phase 3 | NCT03130426 | Jun 2017 → Jun 2019 | type 2 diabetes mellitus | Population Health Research Institute | Completed | No outcome recorded |
| Phase 3 | NCT02855684 | Aug 2016 → Aug 2018 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT02623998 | Jul 2016 → Sep 2018 | type 2 diabetes mellitus | Population Health Research Institute | Completed | No outcome recorded |
| Phase 3 | NCT02787551 | Jul 2016 → May 2018 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT02752412 | May 2016 → Oct 2018 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT02749890 | May 2016 → May 2018 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT02735044 | Apr 2016 → May 2018 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT02607943 | Dec 2015 → Jul 2018 | hyperglycemia, stroke disorder | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT02666430 | Dec 2015 → Mar 2017 | type 1 diabetes mellitus | Mylan Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02585674 | Dec 2015 → Nov 2016 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT02401243 | Mar 2015 → Feb 2016 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT02320721 | Jan 2015 → May 2016 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT02168491 | Nov 2014 → Jul 2015 | type 2 diabetes mellitus | Medical University of Vienna | Completed | No outcome recorded |
| Phase 3 | NCT02194595 | Sep 2014 → Dec 2021 | type 2 diabetes mellitus | Mount Sinai Hospital, Canada | Completed | No outcome recorded |
| Phase 3 | NCT02227212 | Aug → Nov 2014 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT02192424 | Jul 2014 → Aug 2020 | type 2 diabetes mellitus | Mount Sinai Hospital, Canada | Completed | No outcome recorded |
| Phase 3 | NCT02132637 | May 2014 → Jul 2015 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT02030600 | Jan 2014 → Dec 2015 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT02034513 | Jan 2014 → Jan 2016 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01849289 | Jun 2013 → May 2014 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01755468 | Apr 2013 → Oct 2017 | type 2 diabetes mellitus | Mount Sinai Hospital, Canada | Completed | No outcome recorded |
| Phase 3 | NCT01689142 | Sep 2012 → Nov 2013 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01689129 | Sep 2012 → Oct 2013 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01676220 | Aug 2012 → Sep 2013 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01570751 | Apr 2012 → Jan 2014 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01461616 | Feb → Nov 2012 | type 1 diabetes mellitus | University of Aarhus | Completed | No outcome recorded |
| Phase 3 | NCT01499082 | Dec 2011 → Jan 2013 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01499095 | Dec 2011 → Apr 2013 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01136746 | Mar → Nov 2011 | hyperglycemia | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 3 | NCT01223131 | Feb 2011 → Mar 2014 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01272193 | Jan → Sep 2011 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01135992 | Jun → Nov 2010 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01045707 | Jan → Oct 2010 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01006291 | Nov 2009 → Sep 2010 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00993473 | Oct 2009 → Mar 2011 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00851903 | Jun 2009 → Sep 2011 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00943709 | May 2009 → Mar 2010 | hyperglycemia, leukemia | University of Medicine and Dentistry of New Jersey | Withdrawn | No outcome recorded |
| Phase 3 | NCT00640991 | Apr 2008 → Jun 2010 | hyperglycemia, myocardial infarction | Population Health Research Institute | Completed | No outcome recorded |
| Phase 3 | NCT00437112 | Feb 2007 → May 2008 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00355849 | Aug 2006 → Jun 2008 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00331851 | May 2006 → Apr 2007 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00272064 | Oct 2005 → May 2008 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00271284 | Oct 2005 → Sep 2008 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00135941 | Aug 2005 → Sep 2007 | diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00687466 | Aug 2005 → Oct 2009 | cystic fibrosis, glucose intolerance | Fondazione per la ricerca sulla Fibrosi Cistica | Unknown | No outcome recorded |
| Phase 3 | NCT00151697 | May 2005 → ? | type 2 diabetes mellitus | Rijnstate Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00106366 | Mar → Dec 2005 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00097877 | Jan 2005 → Nov 2006 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00174668 | Nov 2004 → Nov 2007 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00097084 | Sep 2004 → Dec 2005 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00099619 | Sep 2004 → Aug 2005 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00095082 | Sep 2004 → Dec 2005 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00500240 | Apr 2004 → Apr 2012 | acute leukemia, lymphoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 3 | NCT00069784 | Aug 2003 → Dec 2011 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00222521 | Apr 2003 → Aug 2005 | cystic fibrosis-related diabetes | University of Minnesota | Completed | No outcome recorded |
| Phase 3 | NCT00283751 | Mar 2003 → Nov 2004 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00046501 | Nov 2002 → Feb 2005 | diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00272090 | Nov 2002 → Dec 2005 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00598793 | Nov 2002 → Mar 2004 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00563225 | Oct 2002 → Apr 2004 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00312104 | Apr 2002 → Mar 2003 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00783744 | Dec 2001 → Aug 2003 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00537251 | Nov 2001 → Feb 2004 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00046462 | Nov 2001 → Nov 2004 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01336751 | Jul 2001 → Dec 2002 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00653341 | Jan 2000 → Oct 2001 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4141 trials | ||||||
| Phase 4 | NCT07117240 | Jul 2025 → Feb 2028 expected | diabetes mellitus, hyperglycemia | Medical University of Warsaw | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT06999551 | Jul → Dec 2025 overdue | type 2 diabetes mellitus | Les Laboratoires des Médicaments Stériles | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07274644 | Mar 2025 → Jun 2026 overdue | metabolic dysfunction-associated steatotic liver disease, type 2 diabetes mellitus | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05614089 | Mar 2023 → Aug 2024 | type 1 diabetes mellitus | Jing Luo | Completed | No outcome recorded |
| Phase 4 | NCT05552859 | Dec 2022 → Jul 2023 | impaired renal function disease, type 2 diabetes mellitus | Sanofi | Terminated | No outcome recorded |
| Phase 4 | NCT06717191 | Jun 2022 → Jun 2024 | type 1 diabetes mellitus | Life for a Child Program, Diabetes Australia | Completed | No outcome recorded |
| Phase 4 | NCT06674135 | Jun 2022 → Aug 2023 | type 1 diabetes mellitus | Life for a Child Program, Diabetes Australia | Completed | No outcome recorded |
| Phase 4 | NCT06624943 | Mar 2022 → May 2023 | type 1 diabetes mellitus | Life for a Child Program, Diabetes Australia | Completed | No outcome recorded |
| Phase 4 | NCT04323462 | Oct 2021 → Nov 2022 | ulcer of lower limbs | Post Graduate Institute of Medical Education and Research, Chandigarh | Unknown | No outcome recorded |
| Phase 4 | NCT04864977 | Aug 2021 → Jun 2022 | type 2 diabetes mellitus | Eli Lilly and Company | Withdrawn | No outcome recorded |
| Show all 141 trials opens the full record — a long page | ||||||
| Phase not applicable24 trials | ||||||
| — | NCT07171684 | Nov 2025 → Oct 2026 expected | gestational diabetes | Rutgers, The State University of New Jersey | Recruiting | No outcome recorded |
| — | NCT06419777 | Sep 2024 → May 2026 overdue | gestational diabetes | Thomas Jefferson University | Recruiting | No outcome recorded |
| — | NCT04553380 | Dec 2020 → Dec 2021 | type 2 diabetes mellitus | Shenzhen Second People's Hospital | Unknown | No outcome recorded |
| — | NCT03829891 | Aug 2018 → Dec 2019 | type 2 diabetes mellitus | Xijing Hospital | Completed | No outcome recorded |
| — | NCT03180281 | Jul 2017 → Jan 2020 | type 2 diabetes mellitus | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
| — | NCT02694289 | Nov 2016 → Sep 2018 | type 2 diabetes mellitus | Maya Guglin | Withdrawn | No outcome recorded |
| — | NCT02930044 | Oct 2016 → Nov 2021 | diabetic ketoacidosis | University of Maryland, Baltimore | Completed | No outcome recorded |
| — | NCT02548494 | Nov 2015 → Feb 2019 | diabetic ketoacidosis, type 1 diabetes mellitus | Chattanooga-Hamilton County Hospital Authority | Terminated | No outcome recorded |
| — | NCT02144441 | Jun → Oct 2014 | diabetes mellitus | University of Pennsylvania | Withdrawn | No outcome recorded |
| — | NCT02204839 | Jan 2014 → Jan 2015 | type 1 diabetes mellitus | Northumbria University | Completed | No outcome recorded |
| — | NCT01974544 | May 2013 → Dec 2015 | type 2 diabetes mellitus | Pontificia Universidad Catolica de Chile | Unknown | No outcome recorded |
| — | NCT02006342 | Nov 2012 → Apr 2013 | diabetic ketoacidosis | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| — | NCT01424046 | May 2011 → Jun 2014 | type 1 diabetes mellitus | University of Pittsburgh | Completed | No outcome recorded |
| — | NCT01335763 | Apr 2011 → Oct 2012 | type 2 diabetes mellitus | University of Alberta | Completed | No outcome recorded |
| — | NCT01276912 | Jan 2011 → Oct 2013 | prediabetes syndrome | Beijing Tongren Hospital | Unknown | No outcome recorded |
| — | NCT01257087 | Dec 2010 → Feb 2016 | obesity disorder, type 2 diabetes mellitus | Imperial College London | Completed | No outcome recorded |
| — | NCT01045954 | Jan → Aug 2010 | type 1 diabetes mellitus | Diabetes Care Center | Unknown | No outcome recorded |
| — | NCT00978263 | Feb 2009 → Dec 2011 | diabetes mellitus | Chongqing Medical University | Completed | No outcome recorded |
| — | NCT00659165 | Apr 2008 → Dec 2010 | diabetes mellitus | University of New Mexico | Completed | No outcome recorded |
| — | NCT00469833 | Apr 2008 → Dec 2011 | hyperglycemia, type 2 diabetes mellitus | US Department of Veterans Affairs | Completed | No outcome recorded |
| — | NCT00457093 | Oct 2006 → May 2007 | type 2 diabetes mellitus | Diabetes Care Center | Completed | No outcome recorded |
| — | NCT00564018 | Sep 2006 → Feb 2009 | type 1 diabetes mellitus | University of Texas Southwestern Medical Center | Terminated | No outcome recorded |
| — | NCT00464854 | Jul 2005 → Sep 2006 | diabetes mellitus | Assaf-Harofeh Medical Center | Terminated | No outcome recorded |
| — | NCT00179127 | Aug 2004 → Jul 2009 | diabetic ketoacidosis | Vanderbilt University Medical Center | Completed | No outcome recorded |
Also used as a comparator or background therapy in 331 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT03400501 Comparator | Oct 2017 → Jun 2021 | type 1 diabetes mellitus | Yale University | Completed | No outcome recorded |
| Phase 0 | NCT02012465 Background | Sep 2013 → May 2015 | hyperglycemia, lymphoma, type 2 diabetes mellitus | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 138 trials | ||||||
| Phase 1 | NCT06627478 Comparator | Oct 2024 → Jul 2025 | — | Xentria, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05596747 Comparator | Nov 2022 → Oct 2023 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05373186 Comparator | May → Dec 2022 | — | Adocia | Completed | No outcome recorded |
| Phase 1 | NCT05373199 Comparator | May → Oct 2022 | type 1 diabetes mellitus | Adocia | Completed | No outcome recorded |
| Phase 1 | NCT05248841 Comparator | Mar → Aug 2022 | type 1 diabetes mellitus, type 2 diabetes mellitus | Lannett Company, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04957914 Comparator | Jul 2021 → Oct 2022 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04575181 Comparator | Oct 2020 → Dec 2021 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT04262661 Comparator | Mar → Sep 2020 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT04136067 Comparator | Oct 2019 → Aug 2020 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT03965013 Comparator | Jun → Dec 2019 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT03367377 Comparator | Jan → Oct 2018 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03170544 Comparator | Aug 2017 → Nov 2018 | type 1 diabetes mellitus, type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT03095651 Comparator | Apr 2017 → Jan 2018 | type 1 diabetes mellitus, type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT03025009 Comparator | Mar 2017 → Apr 2018 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02942914 Comparator | Dec 2016 → Oct 2017 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02915250 Comparator | Oct 2016 → Jun 2017 | type 2 diabetes mellitus | Adocia | Completed | No outcome recorded |
| Phase 1 | NCT02536859 Comparator | Aug 2015 → Apr 2016 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02514850 Comparator | Jul → Nov 2015 | type 2 diabetes mellitus | Adocia | Completed | No outcome recorded |
| Phase 1 | NCT02220296 Comparator | Aug 2014 → Mar 2015 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02197520 Comparator | Jul 2014 → Jun 2015 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02152384 Comparator | Jun → Dec 2014 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01925989 Comparator | Nov 2013 → Oct 2015 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01771250 Comparator | Oct 2013 → Dec 2014 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01796366 Comparator | Feb → Aug 2013 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01784211 Comparator | Feb → Nov 2013 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01769404 Comparator | Feb → Dec 2013 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01600950 Comparator | May → Jul 2012 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01374178 Comparator | Jun → Jul 2011 | diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01152242 Comparator | Aug 2010 → May 2012 | diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT01114542 Comparator | May → Aug 2010 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01153100 Comparator | Apr 2010 → Feb 2012 | diabetes mellitus | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 1 | NCT01030926 Comparator | Dec 2009 → May 2010 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT00964418 Comparator | Aug → Nov 2009 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT00971659 Comparator | Jan → Sep 2008 | type 2 diabetes mellitus | Profil Institute for Metabolic Research GmbH | Completed | No outcome recorded |
| Phase 1 | NCT00511472 Background | Jul 2007 → Apr 2008 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00652288 Comparator | Apr 2007 → Sep 2011 | type 1 diabetes mellitus | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT01865292 Comparator | Aug → Nov 2006 | type 1 diabetes mellitus, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01497535 Comparator | May → Oct 2004 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 218 trials | ||||||
| Phase 2 | NCT06688123 Comparator | Jan 2025 → Apr 2026 | type 2 diabetes mellitus | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT06007508 Comparator | May 2022 → Feb 2023 | diabetic ketoacidosis | HealthPartners Institute | Terminated | No outcome recorded |
| Phase 2 | NCT03951805 Comparator | May → Dec 2019 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2 | NCT03751657 Comparator | Nov 2018 → Dec 2019 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2 | NCT02470039 Comparator | Jun → Dec 2015 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2 | NCT01658579 Comparator | Aug 2012 → May 2013 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT01596504 Background | May 2012 → Jul 2013 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT01476475 Comparator | Nov 2011 → Dec 2012 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT01194258 Background | Aug 2010 → Aug 2011 | type 2 diabetes mellitus | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT01194245 Background | Aug 2010 → Aug 2011 | type 1 diabetes mellitus | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT01027871 Comparator | Jan → Dec 2010 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00883558 Background | May 2009 → Feb 2010 | type 1 diabetes mellitus | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00824616 Background | Jan 2009 → May 2010 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00767000 Background | Oct 2008 → Apr 2010 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 2 | NCT00611884 Comparator | Jan → Aug 2008 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2 | NCT00614055 Comparator | Jan → Jul 2008 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2 | NCT01000922 Background | Jun 2006 → Jan 2008 | diabetes mellitus | Biodel | Completed | No outcome recorded |
| Phase 2 | NCT00147745 Comparator | Jun 2005 → Jan 2008 | type 2 diabetes mellitus | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT05565976 Background | Aug 2020 → Dec 2024 | cognitive impairment with or without cerebellar ataxia, ischemic stroke, metabolic syndrome X, vascular dementia | Jaime Daniel Mondragon | Unknown | No outcome recorded |
| Phase 2/3 | NCT00447213 Background | Apr 2007 → May 2008 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3135 trials | ||||||
| Phase 3 | NCT07076199 Comparator | Aug 2025 → Jan 2027 expected | type 1 diabetes mellitus | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 3 | NCT06767761 Comparator | Feb 2025 → Mar 2026 overdue | type 2 diabetes mellitus | Gan & Lee Pharmaceuticals. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06871761 Comparator | May 2024 → May 2025 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT06619301 Comparator | Apr 2024 → Apr 2026 overdue | gestational diabetes, type 2 diabetes mellitus | Loyola University | Recruiting | No outcome recorded |
| Phase 3 | NCT06107153 Comparator | Nov 2023 → Nov 2024 | type 2 diabetes mellitus | University of Basrah | Completed | No outcome recorded |
| Show all 135 trials opens the full record — a long page | ||||||
| Phase 4109 trials | ||||||
| Phase 4 | NCT07224893 Comparator | May 2026 → Dec 2027 expected | pregnancy disorder | Eastern Virginia Medical School | Recruiting | No outcome recorded |
| Phase 4 | NCT07173712 Comparator | Mar 2026 → Jun 2027 expected | type 2 diabetes mellitus | Yanbing Li | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07112339 Comparator | Aug 2025 → Aug 2026 overdue | type 2 diabetes mellitus | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 4 | NCT06671587 Comparator | Dec 2024 → Sep 2026 expected | type 2 diabetes mellitus | Sanofi | Recruiting | No outcome recorded |
| Phase 4 | NCT06370715 Background | Apr 2024 → Sep 2025 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Show all 109 trials opens the full record — a long page | ||||||
| Phase not applicable27 trials | ||||||
| — | NCT07652528 Comparator | Aug 2026 → Jun 2028 expected | glucose metabolism disease, sudden sensorineural hearing loss | Hallym University | Not yet recruiting | No outcome recorded |
| — | NCT07568574 Background | Mar 2026 → May 2028 expected | — | Enhanced Emirates Limited | Enrolling by invitation | No outcome recorded |
| — | NCT06419803 Comparator | Sep 2024 → May 2026 overdue | gestational diabetes | Thomas Jefferson University | Recruiting | No outcome recorded |
| — | NCT06178874 Comparator | Dec 2023 → May 2024 | glucose metabolism disease | Ain Shams University | Completed | No outcome recorded |
| — | NCT05036876 Comparator | Oct 2021 → Mar 2022 | type 2 diabetes mellitus | Medanta, The Medicity, India | Completed | No outcome recorded |
| — | NCT04965051 Comparator | Aug 2021 → Dec 2023 | type 1 diabetes mellitus | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| — | NCT05219942 Comparator | Dec 2020 → Jun 2022 | chronic kidney disease | Ain Shams University | Unknown | No outcome recorded |
| — | NCT04484779 Background | Jul → Dec 2020 | type 1 diabetes mellitus, type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| — | NCT04101383 Comparator | Oct 2017 → Feb 2018 | — | Geropharm | Completed | No outcome recorded |
| — | NCT03001323 Comparator | Jan 2017 → Jan 2019 | diabetes mellitus | Hennepin Healthcare Research Institute | Terminated | No outcome recorded |
| — | NCT02846233 Comparator | Aug 2016 → Dec 2018 | type 2 diabetes mellitus | University of California, San Francisco | Completed | No outcome recorded |
| — | NCT02222623 Comparator | Apr 2015 → May 2016 | type 2 diabetes mellitus | Inova Health Care Services | Withdrawn | No outcome recorded |
| — | NCT02887625 Comparator | Feb 2015 → May 2017 | type 2 diabetes mellitus | Dr. Muhammad Abdulghani | Unknown | No outcome recorded |
| — | NCT02824510 Comparator | Aug 2014 → Sep 2016 | type 1 diabetes mellitus | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Completed | No outcome recorded |
| — | NCT02026310 Background | Jan 2014 → Nov 2015 | type 2 diabetes mellitus | Qifu Li | Completed | No outcome recorded |
| — | NCT02155023 Background | Jan 2014 → Jan 2015 | diabetes mellitus | Medical University of Graz | Completed | No outcome recorded |
| — | NCT01363609 Comparator | Oct 2011 → Jan 2015 | obesity disorder, type 2 diabetes mellitus | Amsterdam UMC, location VUmc | Completed | No outcome recorded |
| — | NCT01089569 Comparator | Apr 2010 → May 2013 | type 2 diabetes mellitus | HealthPartners Institute | Completed | No outcome recorded |
| — | NCT01855243 Comparator | Mar 2010 → Feb 2014 | type 2 diabetes mellitus | Cairo University | Completed | No outcome recorded |
| — | NCT00925977 Comparator | Jul 2009 → Feb 2012 | type 1 diabetes mellitus | Rabin Medical Center | Terminated | No outcome recorded |
| — | NCT00869414 Comparator | Jul 2009 → Mar 2010 | hypoglycemia, type 1 diabetes mellitus | Johns Hopkins University | Terminated | No outcome recorded |
| — | NCT00855439 Comparator | Jun 2008 → May 2014 | diabetic polyneuropathy, type 2 diabetes mellitus | University of Michigan | Completed | No outcome recorded |
| — | NCT00609986 Comparator | Jul 2007 → Oct 2010 | diabetes mellitus, hyperglycemia | Medical University of South Carolina | Completed | No outcome recorded |
| — | NCT00357890 Comparator | Dec 2005 → Oct 2014 | type 1 diabetes mellitus | Nemours Children's Clinic | Completed | No outcome recorded |
| — | NCT00506194 Background | Oct 2005 → Aug 2007 | type 2 diabetes mellitus | Taipei Veterans General Hospital, Taiwan | Completed | No outcome recorded |
| — | NCT00574405 Comparator | Apr 2005 → Mar 2010 | type 1 diabetes mellitus | Arkansas Children's Hospital Research Institute | Completed | No outcome recorded |
| — | NCT00927524 Comparator | Apr 2005 → Apr 2006 | type 1 diabetes mellitus | Vanderbilt University | Completed | No outcome recorded |
Press releases naming this drug 19 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-03-26 | Novo Nordisk A/S | Novo Nordisk A/S: Awiqli® approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes novonordisk.com ↗ |
| 2024-07-10 | Novo Nordisk A/S | Novo Nordisk receives Complete Response Letter in the US for once-weekly basal insulin icodec novonordisk.com ↗ |
| 2024-03-21 | Novo Nordisk A/S | Awiqli® (once-weekly basal insulin icodec) recommended for approval for the treatment of diabetes by the European regulatory authorities novonordisk.com ↗ |
| 2024-01-08 | Novo Nordisk A/S | COMBINE 3 phase 3a trial successfully completed with once-weekly IcoSema demonstrating non-inferior reduction in HbA1c versus daily basal-bolus treatment (insulin glargine U100 and insulin aspart) in people with type 2 diabetes novonordisk.com ↗ |
| 2023-03-16 | Sanofi | Press Release: Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance sanofi.com ↗ |
| 2022-10-03 | Novo Nordisk A/S | Once-weekly insulin icodec demonstrates superior reduction in HbA1c in combination with a dosing guide app versus once-daily basal insulin in people with type 2 diabetes in ONWARDS 5 phase 3a trial novonordisk.com ↗ |
| 2022-06-03 | Novo Nordisk A/S | Novo Nordisk achieves primary objectives of ONWARDS 1 and 6 trials with once-weekly insulin icodec demonstrating superior reduction in HbA1c vs insulin glargine U100 in ONWARDS 1 novonordisk.com ↗ |
| 2022-04-12 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Mylan Pharmaceuticals Inc., a Viatris Company, Conducting Voluntary Nationwide Recall of One Batch of Insulin Glargine (Insulin glargine-yfgn) Injection, 100 units/mL (U-100), Due to the Potential for a Missing Label in the Batch viatris.com ↗ |
| 2022-01-18 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Mylan Pharmaceuticals Inc., a Viatris Company, Conducting Voluntary Recall of One Batch of Semglee® (insulin glargine injection), 100 units/mL (U-100), 3 mL Prefilled Pens, Due to the Potential for a Missing Label in the Batch viatris.com ↗ |
| 2021-12-29 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Viatris Wins Court Decisions on Sanofi Appeals of Lantus® Patent Invalidations viatris.com ↗ |
| 2021-11-16 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Viatris and Biocon Biologics Announce Launch of Interchangeable SEMGLEE® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection viatris.com ↗ |
| 2021-07-28 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Viatris Inc. and Biocon Biologics Receive Historic Approval for First Interchangeable Biosimilar Semglee® (insulin glargine-yfgn) injection for the Treatment of Diabetes viatris.com ↗ |
| 2016-11-29 | Novo Nordisk A/S | Novo Nordisk A/S: Tresiba® demonstrates a safe cardiovascular profile and reduces the risk of severe hypoglycaemia compared to insulin glargine U100 in the DEVOTE trial novonordisk.com ↗ |
| 2016-02-23 | Novo Nordisk A/S | Tresiba® demonstrates significantly lower rate of hypoglycaemia than insulin glargine U100 in blinded phase 3b trial in people with type 1 diabetes novonordisk.com ↗ |
| 2016-01-29 | Novo Nordisk A/S | Tresiba® demonstrates significantly lower rate of hypoglycaemia than insulin glargine in blinded phase 3b trial in people with type 2 diabetes novonordisk.com ↗ |
| 2011-11-07 | Novo Nordisk A/S | Novo Nordisk A/S: DegludecPlus provides superior glycaemic control compared to insulin glargine in a phase 3a trial in Japanese people with type 2 diabetes novonordisk.com ↗ |
| 2010-12-22 | Novo Nordisk A/S | Degludec significantly reduces risk of hypoglycaemia during the night compared to insulin glargine in two long-term studies novonordisk.com ↗ |
| 2007-06-21 | Novo Nordisk A/S | Liraglutide giver en væsentligt bedre blodsukkerregulering end insulin glargine i fase 3-studie novonordisk.com ↗ |
| 2007-06-21 | Novo Nordisk A/S | Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study novonordisk.com ↗ |
Evidence & citations 62 cited values
Every value below carries the sentence it was read from. 706 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | insulin glargine | “The Glargine/Lispro Protocol included 0.2 unit/kg/day as insulin glargine once daily if the dose was between 40-80 units, or twice daily if the dose was less than 40 or more...” NCT01810952 ↗494“The differences between insulin glargine U300 and insulin degludec U100 in impact on the glycaemic variability, arterial stiffness and the lipid profiles in insulin naïve...” PMID 33926446 ↗ Apr 2021 “INTRODUCTION: LY2963016 insulin glargine (LY IGlar), a biosimilar of Lantus® insulin glargine (IGlar), demonstrated comparable efficacy and safety versus the reference product...” PMID 35471721 ↗ Apr 2022 “Discharge on 0.3 U/kg of admission long acting insulin glargine or detemir (provided by diabetes and endocrine clinic) regardless of participant's home insulin regimen at the...” NCT03001323 ↗ “Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes...” PMID 38558508 ↗ Apr 2024 “Four injections of insulin daily consisting in three bolus of a rapid-acting analog lispro or aspart before breakfast, lunch and dinner and one injection of insulin glargine or...” NCT03463564 ↗ “Lilly insulin glargine (LY IGlar; Basaglar®) and the reference insulin glargine product (IGlar; Lantus®) are basal insulin glargine analogs with identical amino acid sequence...” PMID 31119716 ↗ Aug 2019 “The participants will either be prescribed weekly insulin icodec or a daily basal insulin (insulin glargine, insulin detemir or insulin degludec) based on current standards for...” NCT07112339 ↗ “INTRODUCTION: LY2963016 insulin glargine (LY IGlar) and Lantus® (IGlar), both with identical primary amino acid sequences, were compared in two phase 3 studies for intrapatient...” PMID 29855972 ↗ May 2018 “The study aims to compare insulin glargine, a long-acting basal insulin with approximately 24-hour duration, and insulin degludec, an ultra-long-acting basal insulin with about...” NCT07599891 ↗ “Levemir (insulin detemir) and Lantus (insulin glargine) are two relatively new insulin analogs known for their consistent and reproducible absorption profiles and steady...” NCT00564018 ↗ “This study compared the efficacy and safety of exenatide twice daily or mealtime insulin lispro in patients inadequately controlled by insulin glargine and metformin despite...” PMID 25011946 ↗ Jul 2014 “Subjects will receive FIAsp combined with their pre-trial basal insulin (insulin human, insulin detemir or insulin glargine) treatment in combination with their pre-trial metformin.” NCT01850615 ↗ “OBJECTIVE: Insulin glargine is difficult to use for children due to the number of injections required because it is claimed to be immiscible with rapid-acting insulin analogs.” PMID 18299307 ↗ Feb 2008 “This study analyzed phase III data comparing basal insulin peglispro (BIL) and insulin glargine in type 1 (T1D), and type 2 diabetes (T2D) (insulin-naïve and insulin-treated).” PMID 29167192 ↗ Nov 2017 “Multiple daily injections which consist of a single injection of basal insulin(insulin Glargine) and 3 injections of bolus insulin(rapid acting insulin Glulisine or Aspart)” NCT03112538 ↗ “Patients in Group A (glargine-regular regimen) received insulin glargine (GLA) once in the evening (8:00 pm) and regular insulin 30 minutes before their three main meals.” NCT05709938 ↗ “This open-label, parallel-group, two-arm, pilot study compared the beta-cell protective effect of adding insulin glargine (GLA) vs. NPH insulin to ongoing metformin.” PMID 20415692 ↗ May 2010 “Aim: To compare safety (immunogenicity) and efficacy of GP40061 insulin glargine (GP-Gla) and Lantus® (Sanofi glargine, Sa-Gla) in people with diabetes mellitus.” PMID 32027167 ↗ Feb 2020 “Pioglitazone 15 mg, tablets, orally, twice daily and metformin placebo-matching tablets, orally, twice daily and insulin glargine stable dose for up to 24 weeks.” NCT00770445 ↗ “The main purpose of this study is to evaluate a novel approach for insulin glargine (LY2963016) titration for insulin-naïve adults with type 2 diabetes (T2D)” NCT04864977 ↗ “Those in Group 2 will be treated with a combination of insulin glargine and lixisenatide, with dosages individually adjusted based on current glucose levels.” NCT07117240 ↗ “Linagliptin and bed time insulin glargine linagliptin (trajenta) once daily combined with bed time basal insulin (glargine Lantus; sanofi) before meals” NCT03051243 ↗ “A randomized trial of two weight-based doses of insulin glargine and glulisine in hospitalized subjects with type 2 diabetes and renal insufficiency.” PMID 22699288 ↗ Jun 2012 “Insulin glargine, neutral protamine hagedorn (NPH) insulin, detemir, lente and ultralente were considered as basal insulin.” NCT01798706 ↗ “insulin degludec in comparison with insulin glargine U100 is superior in limiting the occurrence of nocturnal hypoglycaemia” PMID 31337371 ↗ Jul 2019 “Treatment with insulin glargine reduced the incidence of confirmed hypoglycaemia and confirmed nocturnal hypoglycaemia.” PMID 33166419 ↗ Nov 2020 “50% dose in insulin glargine and 50% dose in insulin lispro or aspartic, distributed in equal parts in the 3 main meals” NCT04739241 ↗ “Subjects will take 1 daily injection of insulin glargine in manner consistent with current prescribing guidelines.” NCT00855439 ↗ “record the time when the FPG reached the standard, the total amount of insulin glargine, hypoglycemia and so on.” NCT04553380 ↗ “A dose of insulin glargine, 0.4 unit/kg, will be given within 4 hours from initiating the IV Insulin Infusion” NCT04567225 ↗ “This protocol addresses a comparison of insulin glargine and insulin detemir for patients evaluated by CGMS.” NCT00457093 ↗ “Insulin glargine, marketed by Sanofi Aventis under the name Lantus, is a long-acting basal insulin analogue.” NCT01269996 ↗ “There are no evidence-based guidelines for insulin glargine (Lantus) dosing in the perioperative setting.” NCT00309465 ↗ “Patients also receive long-acting basal insulin therapy (insulin glargine 100 U/mL) throughout the study” NCT07070752 ↗ “Individualized basal insulin (insulin degludec, insulin glargine or insulin detemir) for each patient.” NCT04974528 ↗ “Insulin glargine (rDNA origin) injection solution for subcutaneous (SC) injection, taken once daily.” NCT00824616 ↗ “Insulin Glargine will be administered subcutaneously at the dosage of 0.1 U/Kg/die for three months.” NCT00687466 ↗ “BioChaperone Combo is a liquid formulation containing both Insulin Glargine and Insulin Lispro.” NCT01981031 ↗ “Participants will receive subcutaneous injections of insulin glargine once weekly for 2 weeks.” NCT03723772 ↗ “insulin glargine daily with the addition of insulin lispro given three times daily with meals” NCT00110370 ↗ “Basal insulin glargine has a neutral effect on cardiovascular risk in type 2 diabetes (T2DM).” PMID 36894921 ↗ Mar 2023 “once-daily insulin glargine plus oral agents with respect to postprandial glycaemic control” PMID 16842478 ↗ Jul 2006 “Insulin glargine (Lantus, Sanofi-Aventis) with an initial bedtime starting dose of 10 IU.” NCT01399645 ↗ “Insulin glargine given SC once-daily in conjunction with oral antidiabetic medications.” NCT00551356 ↗ “compared insulin lispro with meals and basal insulin glargine (intervention) vs” PMID 21454236 ↗ Sep 2011 “Insulin glargine is obtained by recombinant DNA technology in Escherichia coli.” NCT02706119 ↗ “Preprandial inhaled insulin regimen and administration of insulin glargine QD” NCT00356421 ↗ “Daily bedtime subcutaneous insulin Glargine in individualized doses.” NCT00699686 ↗ “insulin glargine (Lantus™) once daily subcutaneous will be added.” NCT02752113 ↗ “Insulin glargine (U300), 300 Units/mL, average dose: 30-40 U/day.” NCT05036876 ↗ “Participants will receive insulin glargine U100 s.c. once-daily.” NCT05514535 ↗ “Insulin glargine (Glaritus: 100 U/ml), Penfill® cartridges 3.0ml” NCT01357603 ↗ “a switch to insulin glargine is started for a period of 12 weeks” NCT06999551 ↗ “The study group will receive Insulin Glargine as basal insulin.” NCT00841919 ↗ “subjects receiving insulin glargine, in addition to metformin” NCT02551874 ↗ “All patients will be prescribed insulin glargine once a day.” NCT01257087 ↗ “Insulin glargine rescue medication, injectable, as required.” NCT02036515 ↗ “Early administration of subcutaneous insulin glargine dose” NCT02930044 ↗ “Rapid-acting analogue insulin plus basal insulin glargine” NCT00308308 ↗ “Use of Insulin Glargine to Treat Diabetic Ketoacidosis” NCT00179127 ↗ “metformin followed by glipizide and insulin glargine” PMID 40288809 ↗ Apr 2025 “Lantus (insulin glargine) + Glucophage (Metformin)” NCT00653302 ↗ “basal insulin glargine and pre-meal insulin lispro” NCT02192424 ↗ “Basal insulin glargine and pre-meal insulin lispro” NCT01755468 ↗ “insulin glargine (Lantus®) given subcutaneously” NCT00927524 ↗ “insulin glargine U-100 (hereafter, glargine)” PMID 36129997 ↗ Sep 2022 “Lantus (Insulin Glargine), SC, once daily” NCT03713684 ↗ “Lantus®(Insulin Glargine [rDNA Origin[)” NCT00552370 ↗ “insulin glargine (6 to 20 U at bedtime)” NCT04027023 ↗ “Insulin glargine (Lantus® - Solostar®)” NCT00862875 ↗ “Insulin Glargine or detemir 0.2U/kg qd” NCT03180281 ↗ “Insulin Aspart and Insulin Glargine” NCT04834362 ↗ “insulin glargine insulin glulisine” NCT00474838 ↗ “with insulin glargine (n = 25)” PMID 19336639 ↗ Apr 2009 “Lantus (insulin glargine)” NCT01658579 ↗ “Lantus (insulin glargine)” NCT00979628 ↗ “insulin glargine (Lantus)” NCT00000620 ↗ “Lantus(Insulin Glargine)” NCT01910194 ↗ “Drug: insulin glargine” NCT00612040 ↗ “insulin glargine” NCT01215955 ↗ “Insulin glargine” NCT02033889 ↗ “Insulin glargine” NCT05565976 ↗ |
| Known as | Basaglar | “In 2022, LFAC commenced supplying Basaglar (glargine) insulin with insulin pen devices (HumaPen Ergo ll).” NCT06674135 ↗2“basal long-acting insulin Basaglar/Lantus with gliclazide MR 60 mg OD” NCT03819790 ↗ “receive insulin glargine (Basaglar, Eli Lilly, Indianapolis, IN, USA)” PMID 42409045 ↗ Jul 2026 |
| Known as | Basal Insulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00715624 ↗ |
| Known as | Basalin | “AIM: To evaluate the equivalence of immunogenicity, safety and efficacy of Gan & Lee (GL) Glargine (Basalin®; Gan & Lee Pharmaceutical) with that of the reference product...” PMID 38558508 ↗ Apr 20242“Pharmacokinetic and pharmacodynamic bioequivalence of Gan & Lee insulin analogues aspart (rapilin®), lispro (prandilin®) and glargine (basalin®) with EU- und US-sourced...” PMID 37735841 ↗ Sep 2023 |
| Known as | Detemir insulin | “Detemir insulin” NCT01211730 ↗ |
| Known as | Gan & Lee insulin glargine | “0.4 IU/kg Gan & Lee insulin glargine injection SC, Lantus 0.4 IU/kg injection SC” NCT02506647 ↗ |
| Known as | Gan & Lee Insulin Glargine Injection | “Gan & Lee Insulin Glargine Injection for subcutaneous injection, 100 U/mL, in the integrated, disposable 3.0-mL pre-filled Gan & Lee injector pen.” NCT03371082 ↗ |
| Known as | GL Glargine | “AIM: To evaluate the equivalence of immunogenicity, safety and efficacy of Gan & Lee (GL) Glargine (Basalin®; Gan & Lee Pharmaceutical) with that of the reference product...” PMID 38558508 ↗ Apr 2024 |
| Known as | GL-Gla | “Three phase 1, randomized, double-blind, three-period crossover trials compared single doses of the proposed biosimilar insulin analogues aspart (GL-Asp, n = 36), lispro...” PMID 37735841 ↗ Sep 2023 |
| Known as | GLA | “Patients in Group A (glargine-regular regimen) received insulin glargine (GLA) once in the evening (8:00 pm) and regular insulin 30 minutes before their three main meals.” NCT05709938 ↗2“allocated to treatment with either MET 1,000 mg b.i.d. (n = 36) or insulin glargine (GLA) at bedtime” PMID 23430192 ↗ Feb 2013 “Insulin glargine, dose individually adapted to reach treatment goal (FBG \< 100 mg/dL)” NCT00941148 ↗ |
| Known as | Gla-100 | “This study assessed the efficacy and safety of LixiLan, a fixed-ratio, titratable, combination of 2 units insulin glargine (Gla-100) and 1 μg lixisenatide administered once...” PMID 27284114 ↗ Jun 201611“OBJECTIVE: To compare the efficacy and safety of new insulin glargine 300 units/mL (Gla-300) with glargine 100 units/mL (Gla-100) in people with type 2 diabetes on basal...” PMID 25078900 ↗ Jul 2014 “AIMS: To compare the efficacy and safety of new insulin glargine 300 U/ml (Gla-300) with that of glargine 100 U/ml (Gla-100) in insulin-naïve people with type 2 diabetes using...” PMID 25641260 ↗ Feb 2015 “OBJECTIVE: SENIOR compared the efficacy and safety of insulin glargine 300 units/mL (Gla-300) with glargine 100 units/mL (Gla-100) in older people (≥65 years old) with type 2 diabetes.” PMID 29895556 ↗ Jun 2018 “Gla-100 will be supplied as a 3 mL sterile aqueous solution for SC injection in a pre-filled disposable Gla-100 SoloStar® pen containing 300 U insulin glargine (100 U/mL).” NCT06671587 ↗ “AIM: To compare efficacy and safety of new insulin glargine 300 U/ml (Gla-300) with that of insulin glargine 100 U/ml (Gla-100) in Japanese adults with type 1 diabetes.” PMID 26662964 ↗ Feb 2016 “Insulin glargine 300 U/mL (Gla-300) offers a flatter pharmacodynamic profile than insulin glargine 100 U/mL (Gla-100).” PMID 28661585 ↗ Aug 2017 “The baseline insulin glargine 100 U/mL (Gla-100) dose increased significantly” PMID 35943899 ↗ Aug 2022 “insulin glargine 100 U/mL (Gla-100) is as safe as the standard starting dose” PMID 34286454 ↗ Jul 2021 “insulin glargine 100 U mL (-1) (Gla-100)” PMID 26055218 ↗ Jun 2015 “insulin glargine 100 U/mL (Gla-100)” PMID 29649539 ↗ Apr 2018 “glargine 100 U/ml (Gla-100)” PMID 30160030 ↗ Oct 2018 |
| Known as | Gla-300 | “The clinical benefits of insulin glargine 300 U/ml (Gla-300) have been confirmed in randomized clinical trials (EDITION and BRIGHT) and real-world studies (ATOS, Toujeo-1, and...” PMID 40338497 ↗ May 202516“OBJECTIVE: To compare the efficacy and safety of new insulin glargine 300 units/mL (Gla-300) with glargine 100 units/mL (Gla-100) in people with type 2 diabetes on basal...” PMID 25078900 ↗ Jul 2014 “AIMS: To compare the efficacy and safety of new insulin glargine 300 U/ml (Gla-300) with that of glargine 100 U/ml (Gla-100) in insulin-naïve people with type 2 diabetes using...” PMID 25641260 ↗ Feb 2015 “OBJECTIVE: SENIOR compared the efficacy and safety of insulin glargine 300 units/mL (Gla-300) with glargine 100 units/mL (Gla-100) in older people (≥65 years old) with type 2 diabetes.” PMID 29895556 ↗ Jun 2018 “The TOP1 study investigated the effect of switching from twice-daily (BID) basal insulin to once daily (OD) insulin glargine 300 U/mL (Gla-300) on glycemic control and quality of life.” PMID 38982528 ↗ Jul 2024 “AIM: To compare efficacy and safety of new insulin glargine 300 U/ml (Gla-300) with that of insulin glargine 100 U/ml (Gla-100) in Japanese adults with type 1 diabetes.” PMID 26662964 ↗ Feb 2016 “OBJECTIVE: To compare insulin glargine 300 units/mL (Gla-300) versus insulin degludec 100 units/mL (IDeg-100) in this first head-to-head randomized controlled trial.” PMID 30104294 ↗ Aug 2018 “To date, only limited data comparing the second-generation insulins glargine 300 U/mL (Gla-300) and degludec 100 U/mL (IDeg-100) in people with T1D are available” PMID 32100192 ↗ Feb 2020 “Insulin-naive adults with type 2 diabetes and A1c ≥8% were randomized 1:1 to insulin glargine 300 U/mL (Gla-300) or standard-of-care basal insulin (SOC-BI).” PMID 33509703 ↗ Dec 2020 “AIM: To evaluate the efficacy and safety of insulin glargine 300 U/mL (Gla-300) in people with suboptimally controlled type 2 diabetes (T2D) in China.” PMID 39075925 ↗ Jul 2024 “Objective: To compare real-world outcomes with newer (insulin glargine 300 U/mL; Gla-300) versus standard of care (SoC) basal insulins (BIs)” PMID 31865758 ↗ Jan 2020 “Insulin glargine 300 U/mL (Gla-300) offers a flatter pharmacodynamic profile than insulin glargine 100 U/mL (Gla-100).” PMID 28661585 ↗ Aug 2017 “initiated on once-daily bedtime insulin glargine 300U/ml (Gla-300) versus neutral protamine Hagedorn (NPH) insulin” PMID 33738774 ↗ Mar 2021 “Insulin glargine 300 U/mL (Gla-300) contains the same active ingredient as glargine 100 U/mL (Gla-100)” PMID 27664062 ↗ Sep 2016 “New insulin glargine 300 U mL(-1) (Gla-300)” PMID 26055218 ↗ Jun 2015 “insulin glargine 300 U/ml (Gla-300)” PMID 30160030 ↗ Oct 2018 “insulin glargine 300 U/mL (Gla-300)” PMID 30366067 ↗ Oct 2018 |
| Known as | GLAR | “Data from a multi-center, randomized clinical trial comparing the efficacy/safety of biphasic insulin aspart 70/30 (BIAsp 70/30) vs. glargine (Glar) among insulin naïve type 2...” PMID 17286868 ↗ Feb 20071“receiving insulin glargine (GLAR) + metformin (MET).” PMID 20357372 ↗ Mar 2010 |
| Known as | glarg | “twice-daily biphasic insulin aspart 30 (30% soluble and 70% protaminated insulin aspart; BIAsp 30) plus metformin (met) was compared with once-daily insulin glargine (glarg)...” PMID 17115351 ↗ Oct 2006 |
| Known as | glargine | “The aim of this trial is to compare efficacy and safety of NN1250 (insulin degludec (IDeg)) with insulin glargine (IGlar), as add-on to subject's ongoing treatment with...” NCT01068665 ↗82“The DURABLE (Assessing the DURAbility of Basal vs Lispro Mix 75/25 Insulin Efficacy) trial will compare the ability of glargine once daily vs lispro mix 75/25 (75% insulin...” PMID 19885269 ↗ Sep 2008 “Patients were randomized to receive a premixed human insulin formulation with 70% intermediate insulin plus 30% regular insulin (Mixtard 30®, Novo Nordisk) or a basal-bolus...” NCT02333851 ↗ “This 52-week multinational, randomised, open-label, parallel-group, non-inferiority trial compared clinical outcomes following supplementation of oral glucose-lowering drugs...” PMID 18204830 ↗ Jan 2008 “Discharge on 0.3 U/kg of admission long acting insulin glargine or detemir (provided by diabetes and endocrine clinic) regardless of participant's home insulin regimen at the...” NCT03001323 ↗ “clinicians can choose between glucagon-like peptide-1 (GLP-1) receptor agonists and basal insulins. In DURATION-3, exenatide once weekly was compared with insulin glargine...” PMID 24731672 ↗ Apr 2014 “Nine patients with T2DM currently receiving iPremix formulations and poor glycemic control were switched to once-daily injected lixisenatide (Lixi) and basal insulin analogue...” PMID 28357772 ↗ Mar 2017 “The primary endpoint was assessment of the noninferiority of dulaglutide 1.5 mg as measured by change in HbA1c, compared with insulin glargine (glargine), using a 0.4%...” PMID 31228090 ↗ Jun 2019 “AIMS: This study assessed the efficacy and safety of once-daily insulin initiation using insulin detemir (detemir) or insulin glargine (glargine) added to existing metformin in...” PMID 23421331 ↗ Mar 2013 “This randomized, double-blind, crossover trial compared the within-subject variability of detemir and insulin glargine (glargine) in pharmacokinetic properties in children and...” PMID 18761644 ↗ Aug 2008 “The aim of present study is to assess whether if basal insulin, glargine, could improve insulin secretory function of β-cells compared with glimepiride when metformin alone was failed.” PMID 24445656 ↗ Jan 2014 “The AT.LANTUS study investigated optimal methods to initiate and maintain insulin glargine (LANTUS, glargine, Sanofi-aventis, Paris, France) therapy using two treatment algorithms.” PMID 18355327 ↗ Mar 2008 “We conducted a randomized crossover design clinical trial to compare glargine with ultralente insulin as a basal insulin in type 1 diabetes.” PMID 15616226 ↗ Jan 2005 “the long-acting "basal" insulin glargine (Lantus®, Sanofi Aventis Pharmaceuticals) has been shown to facilitate glycemic control” NCT00590044 ↗ “Patients in this arm will continue the basal insulin (glargine, degludec or glargine-300) used before the randomization.” NCT04196231 ↗ “A weight-based basal bolus insulin regimen starting with 0.1 units/kg/day of Glargine and 4 units/meal of Glulisine.” NCT01087567 ↗ “Prior to discharge, all subjects will receive a regimen that includes a daily dose of long-acting insulin (Glargine)” NCT04157738 ↗ “Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals” NCT02004366 ↗ “insulin detemir (detemir) was noninferior to insulin glargine (glargine) as the basal insulin” PMID 19922879 ↗ Oct 2009 “Basal insulin with glargine or detemir will be used as per the hospital formulary.” NCT04416269 ↗ “During this arm/phase patients take subcutaneous glargine daily for 3 months.” NCT00699686 ↗ “Patients were randomized to either NPL (Lilly) or glargine (Lantus, Aventis)” NCT00641407 ↗ “long acting insulin analogues such as detemir o glargine will be added.” NCT01974544 ↗ “once-daily basal insulin (LY2605541 or glargine) plus mealtime insulin” PMID 23193209 ↗ Nov 2012 “(Glargine, Lantus, Sanofi-Aventis, or Detemir, Levemir, Novo Nordisk)” NCT02204839 ↗ “once-weekly efsitora or once-daily insulin glargine U100 (glargine).” PMID 40548694 ↗ Jun 2025 “and with glargine administered subcutaneously before sleep” NCT04690309 ↗ “Subcutaneous insulin (aspart, glargine, detemir)” NCT00764556 ↗ “insulin glargine 300 units/mL (glargine U300)” PMID 32306247 ↗ Apr 2020 “insulin glargine U-100 (hereafter, glargine)” PMID 36129997 ↗ Sep 2022 “insulin glargine (glargine)” PMID 38907935 ↗ Jun 2024 “Glargine, Detemir, Degludec” NCT02767596 ↗ “Biological: Glargine” NCT01357603 ↗ “Glargine” NCT02012465 ↗ “Glargine” NCT04542148 ↗ |
| Known as | Glargine and insulin aspart or lispro | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00464854 ↗ |
| Known as | glargine insulin | “Our trial is designed to compare morning NPH insulin (isophane insulin) with conventional therapy of basal glargine insulin on both continuous blood glucose levels and...” NCT01963728 ↗19“To determine whether the use of glargine insulin as a basal insulin would result in a comparable HbA1c and less glycemic variation and hypoglycemia than ultralente insulin, 22...” PMID 15616226 ↗ Jan 2005 “Single dose glargine insulin (basal component) + regular insulin within total parenteral nutrition (TPN) reservoir (prandial component).” NCT02706119 ↗ “Glargine insulin; 300 Units/mL, average dose: 10-20 U/day; Insulin lispro 100 Units/mL, average dose: 10-30 U/day” NCT05457933 ↗ “with long acting basal glargine insulin and pre-meal insulin analogues” NCT00464854 ↗ “Drug: Glargine insulin was administered per above.” NCT01810952 ↗ “Glargine insulin vs regular insulin” NCT00177398 ↗ “Drug: Glargine insulin” NCT07599891 ↗ “glargine insulin” NCT01211730 ↗ |
| Known as | glargine U100 | “The purpose of this study was to compare the glycemic response to treatment with glargine U100 or neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes...” PMID 31383366 ↗ Aug 20194“compare day-to-day fasting SMBG variability between treatments with insulin degludec (degludec) and insulin glargine 100 units/mL (glargine U100)” PMID 30362250 ↗ Nov 2018 “Participants were randomly assigned in a 1:1 ratio to receive once-weekly insulin icodec or once-daily insulin glargine U100.” PMID 37356066 ↗ Jun 2023 “insulin glargine 100 units/mL (glargine U100)” PMID 30097995 ↗ Aug 2018 |
| Known as | Glargine U300 | “The differences between insulin glargine U300 and insulin degludec U100 in impact on the glycaemic variability, arterial stiffness and the lipid profiles in insulin naïve...” PMID 33926446 ↗ Apr 20212“Glargine U300 is a long-acting human insulin analog indicated to improve glycemic control in adults with diabetes mellitus.” NCT05036876 ↗ |
| Known as | Glaritus | “between the two long-acting insulin glargine formulations, Lantus® and Wockhardt's Glaritus® in subjects with type1 diabetes” NCT01357603 ↗ |
| Known as | GP-Gla | “Aim: To compare safety (immunogenicity) and efficacy of GP40061 insulin glargine (GP-Gla) and Lantus® (Sanofi glargine, Sa-Gla) in people with diabetes mellitus.” PMID 32027167 ↗ Feb 2020 |
| Known as | GP40061 | “Aim: To compare safety (immunogenicity) and efficacy of GP40061 insulin glargine (GP-Gla) and Lantus® (Sanofi glargine, Sa-Gla) in people with diabetes mellitus.” PMID 32027167 ↗ Feb 2020 |
| Known as | HOE901 | “Insulin glargine U300 (new formulation of insulin glargine) HOE901” NCT02227212 ↗28“Insulin glargine/lixisenatide (HOE901/AVE0010)” NCT02058160 ↗ “Insulin glargine/Lixisenatide (HOE901/AVE0010)” NCT02752412 ↗ “Insulin glargine/Lixisenatide (HOE901/AVE0010)” NCT02749890 ↗ “Insulin glargine new formulation (HOE901)” NCT01689142 ↗ “Insulin glargine new formulation (HOE901)” NCT01689129 ↗ “Insulin glargine new formulation HOE901” NCT01838083 ↗ “Insulin Glargine (HOE901)/NPH Insulin” NCT00941369 ↗ “Insulin Glargine (HOE901) [Lantus]” NCT00949442 ↗ “Drug: INSULIN GLARGINE (HOE901)” NCT00950534 ↗ “insulin glargine U200 HOE901” NCT02201199 ↗ “INSULIN GLARGINE (HOE901)” NCT00965549 ↗ “Insulin glargine (HOE901)” NCT02752828 ↗ “Insulin glargine (HOE901)” NCT03798054 ↗ “Insulin glargine (HOE901)” NCT03798080 ↗ “Insulin glargine (HOE901)” NCT01223131 ↗ “Insulin glargine (HOE901)” NCT01195454 ↗ “INSULIN GLARGINE (HOE901)” NCT01234597 ↗ “Insulin glargine (HOE901)” NCT03211858 ↗ “insulin glargine (HOE901)” NCT01676233 ↗ “INSULIN GLARGINE (HOE901)” NCT03529123 ↗ “insulin glargine (HOE901)” NCT00069784 ↗ “INSULIN GLARGINE HOE 901” NCT01461577 ↗ “Insulin glargine HOE901” NCT01053728 ↗ “insulin glargine HOE901” NCT02294474 ↗ “Insulin glargine HOE901” NCT01146678 ↗ “Insulin glargine HOE901” NCT02200991 ↗ “Insulin glargine HOE901” NCT01493115 ↗ “Insulin glargine HOE901” NCT02713477 ↗ |
| Known as | HOE901 - U100 | “Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily (evening) for 12 months on top of non-insulin antihyperglycemic drug(s). Dose titration seeking fasting...” NCT01676220 ↗5“Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily (evening) for 12 months on top of mealtime insulin analogue.” NCT01499082 ↗ “Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily in morning or evening for 12 months” NCT01683266 ↗ “Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily in morning” NCT01658579 ↗ “Lantus (HOE901-U100, insulin glargine 100 U/mL)” NCT01499095 ↗ “Insulin Glargine (HOE901 - U100)” NCT02320721 ↗ |
| Known as | HOE901 - U300 | “morning injection of Toujeo (HOE901-U300) compared to Lantus provides better glycemic control” NCT02688933 ↗6“HOE901-U300 (new formulation of insulin glargine)” NCT01676220 ↗ “HOE901-U300 (new formulation of insulin glargine)” NCT01499095 ↗ “HOE901-U300 (Insulin glargine new formulation)” NCT01683266 ↗ “Insulin Glargine (HOE901 - U300)” NCT02320721 ↗ “Insulin Glargine (HOE901 - U300)” NCT07173712 ↗ |
| Known as | IGla | “This treat-to-target study compared the efficacy and safety of insulin detemir (IDet) and insulin glargine (IGla) in a basal-bolus (insulin aspart) regimen in type 2 diabetes.” PMID 19565569 ↗ Sep 2009 |
| Known as | iGlar | “The aim of this trial is to compare efficacy and safety of NN1250 (insulin degludec (IDeg)) with insulin glargine (IGlar), as add-on to subject's ongoing treatment with...” NCT01068665 ↗32“The aim of this clinical trial is to compare the efficacy and safety of NN1250 (insulin degludec (IDeg)) with insulin glargine (IGlar) in subjects with type 2 diabetes...” NCT01068678 ↗ “AIMS: To assess efficacy and safety of fixed-ratio (1:1) combination insulin glargine and lixisenatide (iGlarLixi) compared to insulin glargine U100 (iGlar), with metformin, in...” PMID 32072742 ↗ Sep 2020 “participants (mean: 45.8 years old, A1C 8.4%, fasting plasma glucose [FPG] 9.9 mmol/L, BMI 26.9 kg/m(2)) received subcutaneous injections of IDeg(A) (600 μmol/L; n = 59),...” PMID 21270174 ↗ Jan 2011 “INTRODUCTION: LY2963016 insulin glargine (LY IGlar), a biosimilar of Lantus® insulin glargine (IGlar), demonstrated comparable efficacy and safety versus the reference product...” PMID 35471721 ↗ Apr 2022 “a novel titratable fixed-ratio combination of insulin glargine (iGlar) and lixisenatide (Lixi), compared with both components, iGlar and Lixi, given separately in type 2...” PMID 27527848 ↗ Aug 2016 “The objective of this study was to compare initiation of a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) vs insulin glargine U100 (iGlar) along with...” PMID 35752566 ↗ Feb 2022 “We examined insulin antibody formation in patients with type 1 (T1D) or type 2 diabetes (T2D) treated with once-daily insulin degludec (IDeg) or insulin glargine (IGlar) to...” PMID 26663320 ↗ Feb 2016 “This trial is conducted in Europe. The aim of the trial is to compare the effect of exercise on blood glucose in subjects with type 1 diabetes, who are treated with either...” NCT01704417 ↗ “Insulin degludec (IDeg) is a new-generation basal insulin with an ultra-long duration of action. We compared the pharmacodynamic (PD) variability of IDeg and insulin glargine...” PMID 22594461 ↗ Jun 2012 “Nine patients with T2DM currently receiving iPremix formulations and poor glycemic control were switched to once-daily injected lixisenatide (Lixi) and basal insulin analogue...” PMID 28357772 ↗ Mar 2017 “Lilly insulin glargine (LY IGlar; Basaglar®) and the reference insulin glargine product (IGlar; Lantus®) are basal insulin glargine analogs with identical amino acid sequence...” PMID 31119716 ↗ Aug 2019 “The objective of this trial was to confirm the efficacy and compare the safety of insulin degludec (IDeg) with insulin glargine (IGlar) in a multinational setting with two...” PMID 27098525 ↗ Jun 2016 “INTRODUCTION: LY2963016 insulin glargine (LY IGlar) and Lantus® (IGlar), both with identical primary amino acid sequences, were compared in two phase 3 studies for intrapatient...” PMID 29855972 ↗ May 2018 “AIMS: To confirm non-inferiority of insulin degludec/insulin aspart (IDegAsp) once-daily (OD) versus insulin glargine (IGlar) U100 OD + insulin aspart (IAsp) OD for HbA1c after 26 weeks” PMID 30448451 ↗ Nov 2018 “compared with insulin glargine U100 (iGlar) in Japanese patients with type 2 diabetes mellitus (T2DM) inadequately controlled on oral antidiabetic drugs (OADs).” PMID 32291880 ↗ Sep 2020 “Subjects were randomized to once-daily injections of IDegAsp (n = 147) or insulin glargine (IGlar) (n = 149), both ±≤2 oral antidiabetic treatments.” PMID 23557077 ↗ Apr 2013 “The aim of this analysis was to compare the effect of IDeg on FPG and nocturnal confirmed hypoglycaemia as compared to insulin glargine (IGlar).” PMID 26232910 ↗ Jun 2015 “We characterize the steady-state (SS) pharmacokinetic/pharmacodynamic properties of insulin degludec (IDeg) versus insulin glargine (IGlar).” PMID 26086190 ↗ Jun 2015 “The acute physiological responses to hypoglycaemia with IDeg and insulin glargine (A21Gly,B31Arg,B32Arg human insulin; IGlar) were compared.” PMID 24057153 ↗ Sep 2013 “The aim of this clinical trial is to compare NN1250 (insulin degludec (IDeg) with insulin glargine (IGlar) in patients with type 2 diabetes.” NCT01006291 ↗ “Subjects received a single subcutaneous dose of 0.4 U/kg IDeg or insulin glargine (IGlar), respectively, on two separate dosing visits” PMID 24467565 ↗ Feb 2014 “The aim of the trial is to confirm the efficacy of IDeg (insulin degludec) versus IGlar (insulin glargine) in controlling glycaemia.” NCT01570751 ↗ “provided similar glycaemic control when injected three times a week (IDeg 3TW) to once-daily insulin glargine (IGlar OD).” PMID 24622318 ↗ Jul 2013 “once daily biphasic insulin aspart 30 (BIAsp 30) is noninferior to once daily insulin glargine (IGlar)” PMID 23998560 ↗ Sep 2013 “compare NN1250 (insulin degludec (IDeg)) with insulin glargine (IGlar)” NCT00972283 ↗ “after beinaglutide alone or combined with insulin glargine (IGlar).” PMID 37864379 ↗ Oct 2023 “insulin glargine (IGlar U100) 20-50 units/day” PMID 29483185 ↗ Feb 2018 “insulin glargine 100 U (iGlar)” PMID 29974618 ↗ Aug 2018 “insulin glargine U100 (IGlar)” PMID 27760129 ↗ Oct 2016 “insulin glargine U100 (IGlar)” PMID 27595693 ↗ Jun 2016 “insulin glargine (IGlar)” NCT03689374 ↗ |
| Known as | IGlar U100 | “BACKGROUND: Durability of glycaemic control might reduce disease burden and improve long-term outcomes. DUAL VIII investigated the durability of insulin degludec plus...” PMID 31189519 ↗ Jun 20193“IDegLira was compared with continued up-titration of insulin glargine (IGlar U100) in DUAL V” PMID 31705547 ↗ Nov 2019 “or once-daily insulin glargine 100 units/mL (IGlar U100)” PMID 33875484 ↗ Apr 2021 “Drug: IGlar U100” NCT07274644 ↗ |
| Known as | IGlar-300 | “There is an ongoing discussion about possible differences between insulin degludec (IDeg-100) and glargine U300 (IGlar-300).” PMID 35802405 ↗ Jul 2022 |
| Known as | IGlar-U300 | “AIM: To compare day-to-day and within-day variability in glucose-lowering effect between insulin degludec (IDeg) and insulin glargine 300 U/mL (IGlar-U300) in type 1 diabetes.” PMID 28295934 ↗ Apr 2017 |
| Known as | iGlarLixi | “To evaluate efficacy and safety of LixiLan (iGlarLixi), a novel titratable fixed-ratio combination of insulin glargine (iGlar) and lixisenatide (Lixi), compared with both...” PMID 27527848 ↗ Aug 2016 |
| Known as | Insulin analog glargine | “Basal bolus Insulin analog glargine (Lantus®) to be injected subcutaneously.” NCT01352663 ↗ |
| Known as | INSULIN GLARGINE (HOE901) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03359837 ↗ |
| Known as | insulin glargine 300U/ml | “initiated on once-daily bedtime insulin glargine 300U/ml (Gla-300) versus neutral protamine Hagedorn (NPH) insulin” PMID 33738774 ↗ Mar 2021 |
| Known as | insulin glargine U100 | “Participants will either get the new insulin 965 or the already marketed insulin glargine U100 (Lantus®)” NCT04136067 ↗2“insulin glargine U100 (glargine U100)” PMID 37156252 ↗ May 2023 “insulin glargine U100 (IGlar)” PMID 27595693 ↗ Jun 2016 |
| Known as | Insulin glargine U300 | “Insulin glargine U300 (new formulation of insulin glargine) HOE901” NCT02227212 ↗ |
| Known as | insulin glargine U300/ml | “This is a 24 week, multicentre, prospective, randomized, controlled, parallel-designed (1:1) pilot study.The study will compare glycemic variability in patients treated with...” NCT03389490 ↗ |
| Known as | insulin glargine-Lantus | “insulin glargine (Lantus)” NCT00000620 ↗ |
| Known as | Insulin glargine/lixisenatide Fixed Ratio Combination | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02058147 ↗ |
| Known as | insulin glargine: Lamtus | “insulin glargine: Lamtus” NCT01461616 ↗ |
| Known as | Insuline glargine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00272077 ↗ |
| Known as | Lantus | “12-week, Multicenter, Controlled, Open, 3:1 Randomized, Parallel Clinical Trial Comparing Insulin Glulisine With Regular Human Insulin (Insulin Lispro) Injected Subcutaneously...” NCT00467376 ↗90“This study will compare how well regular insulin will compare to glargine (Lantus®) once daily plus glulisine (Apidra®) insulin before meals in hospitalized patients with type...” NCT00394407 ↗ “Lilly insulin glargine (LY IGlar; Basaglar®) and the reference insulin glargine product (IGlar; Lantus®) are basal insulin glargine analogs with identical amino acid sequence...” PMID 31119716 ↗ Aug 2019 “INTRODUCTION: LY2963016 insulin glargine (LY IGlar) and Lantus® (IGlar), both with identical primary amino acid sequences, were compared in two phase 3 studies for intrapatient...” PMID 29855972 ↗ May 2018 “The AT.LANTUS study investigated optimal methods to initiate and maintain insulin glargine (LANTUS, glargine, Sanofi-aventis, Paris, France) therapy using two treatment algorithms.” PMID 18355327 ↗ Mar 2008 “Lantus® (insulin glargine injection) solution for subcutaneous injection, 100 U/mL, in the SoloStar® 3.0 mL pre-filled insulin pen.” NCT03371082 ↗ “the long-acting "basal" insulin glargine (Lantus®, Sanofi Aventis Pharmaceuticals) has been shown to facilitate glycemic control” NCT00590044 ↗ “Participants will get either the new insulin 965 or insulin glargine - a medicine that doctors already can prescribe (Lantus®).” NCT04575181 ↗ “pre-meal insulin glulisine (Apidra) versus post-meal Apidra, in patients receiving insulin glargine (Lantus) as basal insulin.” NCT00135096 ↗ “The aim of this extension study is to assess the safety and efficacy of Mylan's insulin glargine and Lantus® in T1DM patients.” NCT02666430 ↗ “between the two long-acting insulin glargine formulations, Lantus® and Wockhardt's Glaritus® in subjects with type1 diabetes” NCT01357603 ↗ “Participants receive Lantus (insulin glargine U-100) once daily in the morning (45% of study TDD) with steroid.” NCT07652528 ↗ “They will be initiated on daily insulin glargine (Lantus®) in addition to their usual OAD regimen for 24 weeks.” PMID 27669747 ↗ Sep 2016 “Insulin glargine, marketed by Sanofi Aventis under the name Lantus, is a long-acting basal insulin analogue.” NCT01269996 ↗ “Lantus (insulin glargine \[rDNA origin\] injection), individual dosing , subcutaneous injection, 100 IU/ml.” NCT00518427 ↗ “Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily in morning or evening for 12 months” NCT01683266 ↗ “There are no evidence-based guidelines for insulin glargine (Lantus) dosing in the perioperative setting.” NCT00309465 ↗ “insulin glargine (Lantus), a long acting analog, may be used when mixed with short acting insulin analogs” NCT01269047 ↗ “Participants will either get the new insulin 965 or the already marketed insulin glargine U100 (Lantus®)” NCT04136067 ↗ “Injection of Lantus® insulin once daily and rapid insulin Apidra® before breakfast, lunch and dinner” NCT02333851 ↗ “patients with type 2 diabetes treated with insulin glargine (Lantus®) and glimepiride (Amaryl®)” NCT00258804 ↗ “Patients were randomized to either NPL (Lilly) or glargine (Lantus, Aventis)” NCT00641407 ↗ “basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir])” NCT00467649 ↗ “(Glargine, Lantus, Sanofi-Aventis, or Detemir, Levemir, Novo Nordisk)” NCT02204839 ↗ “basal long-acting insulin Basaglar/Lantus with gliclazide MR 60 mg OD” NCT03819790 ↗ “originator insulin glargine, Lantus (Sa-Gla), in people with type 1” PMID 29766635 ↗ Jun 2018 “Insulin Glargine (Lantus) once daily at individually adjusted dose” NCT04591457 ↗ “Insulin glargine: Lantus® (100 U/ml) in TactiPen® re-usable pen” NCT00941369 ↗ “Basal insulin (NPH, Lantus, Levimir, Toujeo or Tresiba)” NCT02846233 ↗ “Levemir/Lantus/Tresiba plus NovoLog/Humalog/Apidra” NCT04965051 ↗ “Lantus (insulin glargine [rDNA origin] injection)” NCT00046501 ↗ “Lantus (insulin glargine [rDNA origin] injection)” NCT00046462 ↗ “insulin glargine (Lantus®) given subcutaneously” NCT00927524 ↗ “Lantus (commercial formulation, Reference):” NCT00553020 ↗ “Lantus (Insulin Glargine), SC, once daily” NCT03713684 ↗ “Lantus®(Insulin Glargine [rDNA Origin[)” NCT00552370 ↗ “basal insulin (glargine Lantus; sanofi)” NCT03051243 ↗ “Lantus, drug class: long-acting insuiln” NCT02219750 ↗ “Lantus (insulin glargine) SoloSTAR pen” NCT01226043 ↗ “Insulatard, Actrapid, Lantus, monotard” NCT00506194 ↗ “Insulin Glargine (HOE901) [Lantus]” NCT00949442 ↗ “Drug: Insulin Glargine (Lantus®)” NCT03437330 ↗ “Lantus, Levemir, Novolog, Lispro” NCT02811484 ↗ “Long acting insulin (Lantus)” NCT01100125 ↗ “eg. Humulin, Lantus, Novalin” NCT02694289 ↗ “1. Insulin glargine: Lantus” NCT02027753 ↗ “Insulin Glargine (Lantus®)” NCT00391027 ↗ “Lantus® (insulin glargine)” NCT00348972 ↗ “Lantus (insulin glargine)” NCT00700622 ↗ “Insulin Glargine (Lantus)” NCT02942914 ↗ “insulin glargine (Lantus)” NCT01146678 ↗ “Insulin glargine (Lantus)” NCT00147745 ↗ “Insulin Glargine (LANTUS)” NCT00670228 ↗ “Insulin Glargine (Lantus)” NCT00367445 ↗ “Lantus(Insulin Glargine)” NCT01910194 ↗ “Drug: Lantus (glargine)” NCT00694122 ↗ “Lantus/ Levemir” NCT01269034 ↗ “LANTUS” NCT00511472 ↗ “Lantus” NCT02155023 ↗ “Lantus” NCT06419803 ↗ “Lantus” NCT06419777 ↗ |
| Known as | Lantus (glargine) | “Lantus (glargine)” NCT01378117 ↗ |
| Known as | LANTUS (insulin glargine [rDNA origin] injection | “LANTUS (insulin glargine [rDNA origin] injection” NCT02216799 ↗ |
| Known as | Lantus (insulin glargine) | “Lantus (insulin glargine)” NCT00979628 ↗ |
| Known as | Lantus insulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02365233 ↗ |
| Known as | Lantus is brand name for Glargine | “Lantus is brand name for Glargine” NCT00338104 ↗ |
| Known as | LantusT | “either insulin glargine (LantusT) or NPH-insulin (Protaphan)” NCT00553020 ↗ |
| Known as | MYL-1501D | “BACKGROUND: MYL-1501D is a proposed biosimilar to insulin glargine.” PMID 34174848 ↗ Jun 2021 |
| Known as | Mylan insulin glargine | “Patients will be administered either Mylan insulin glargine or Lantus® subcutaneously, once daily in combination with lispro and titrated based on blood glucose readings per...” NCT02666430 ↗ |
| Known as | Mylan's insulin glargine | “The aim of this extension study is to assess the safety and efficacy of Mylan's insulin glargine and Lantus® in T1DM patients.” NCT02666430 ↗ |
| Known as | SA IGlar | “To compare efficacy and safety of Basaglar® [insulin glargine 100 units/mL; LY insulin glargine (LY IGlar)] to Lantus® [insulin glargine 100 units/mL; SA insulin glargine (SA...” PMID 29542012 ↗ Mar 2018 |
| Known as | SA insulin glargine | “To compare efficacy and safety of Basaglar® [insulin glargine 100 units/mL; LY insulin glargine (LY IGlar)] to Lantus® [insulin glargine 100 units/mL; SA insulin glargine (SA...” PMID 29542012 ↗ Mar 2018 |
| Known as | Sa-Gla | “Aim: To compare safety (immunogenicity) and efficacy of GP40061 insulin glargine (GP-Gla) and Lantus® (Sanofi glargine, Sa-Gla) in people with diabetes mellitus.” PMID 32027167 ↗ Feb 20202“AIM: To compare the efficacy and safety of MK-1293 insulin glargine (Mk-Gla) and Lantus (Sa-Gla) in people with type 2 diabetes mellitus (T2DM).” PMID 29761615 ↗ Jun 2018 “originator insulin glargine, Lantus (Sa-Gla), in people with type 1” PMID 29766635 ↗ Jun 2018 |
| Known as | Sanofi glargine | “Aim: To compare safety (immunogenicity) and efficacy of GP40061 insulin glargine (GP-Gla) and Lantus® (Sanofi glargine, Sa-Gla) in people with diabetes mellitus.” PMID 32027167 ↗ Feb 2020 |
| Known as | Toujeo | “Basal insulin (NPH, Lantus, Levimir, Toujeo or Tresiba)” NCT02846233 ↗ |
| Known as | Toujeo SoloStar | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03328845 ↗ |
| Known as | US-approved Lantus | “The purpose of this study is to compare the pharmacokinetics and pharmacodynamics of LY2963016 and US-approved Lantus®.” NCT01688635 ↗ |
| Known as | US-Lantus | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06627478 ↗ |
| Action | Inhibit | “Glargine lowers blood glucose by mainly inhibiting EGP” PMID 20357371 ↗ Mar 2010 |
| Modality | Protein / enzyme biologic | “Lantus (insulin glargine [rDNA origin] injection)” NCT00046501 ↗ |
| Route | Subcutaneous | “Insulin glargine once daily by subcutaneous injection” NCT00069784 ↗ |